Oncolytics Biotech (ONCY) Stock
Small biotech testing virus treatments for cancer. Here's the price, business snapshot, and what's worth knowing about Oncolytics Biotech in October 2026.
Oncolytics Biotech Inc (ONCY) is a clinical-stage biotechnology company developing pelareorep (also known as REOLYSIN), a reovirus-based oncolytic immunotherapy intended to selectively infect and kill tumour cells and stimulate anti-tumour immune responses. The company is focused on combination studies pairing pelareorep with chemotherapy, immune checkpoint inhibitors and other agents across multiple solid tumour indications. With a market capitalisation around $108.12M, Oncolytics is a small-cap, research-driven business with typical biotech dynamics: value is largely tied to clinical trial readouts, regulatory progress and partnerships. Investors should expect high volatility, potential dilution from financing, and long development timelines. While the mechanism has scientific rationale and some encouraging early data, outcomes are uncertain. This summary is for general educational purposes only and is not investment advice; investors should consider their risk tolerance and seek personalised financial guidance before making decisions.
Oncolytics Biotech (ONCY) Stock Forecast
Analyst price target, next 12 months
$4.50
+795.8% vs today's $0.50
Price range over the last 12 months
Close to its 12-month low
Analysts covering Oncolytics Biotech have a consensus 12-month target of $4.50, above the current price of $0.50.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ONCOLYTICS BIOTECH INC's stock with a target price of $4.5, indicating strong growth potential.
Financial Health
Oncolytics Biotech is generating steady cash flow, but may need to improve profitability and revenue.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage immunotherapy
Pelareorep aims to both kill tumour cells and boost anti-tumour immunity; trial readouts can materially affect prospects, though results are uncertain.
Combination therapy focus
Many studies pair pelareorep with chemo or immune checkpoint inhibitors — partnerships could de‑risk development but regulatory hurdles remain.
Speculative small-cap
Market cap near $108M implies higher volatility and potential dilution; suitable for investors who accept biotech-specific risks and long timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
